Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin Alfa in Hereditary Antithrombin (AT) Deficient Patients in High-Risk Situations for Thrombosis

NCT00110513 is registered in ClinicalTrials.gov with rEVO Biologics as lead sponsor.

NCT NCT00110513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00110513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin Alfa in Hereditary Antithrombin (AT) Deficient Patients in High-Risk Situations for Thrombosis
Lead sponsor
rEVO Biologics
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2005
Completion date
July 31, 2008
Enrollment
18 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

antithrombin iii deficiency